UNSPSC 51152033: Inaperisone

This classification denotes a muscle relaxant with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0QAC3P785O, chemically known as 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pyrrolidinyl)-, but generally known as inaperisone, which bears US NIH Compound Identifier 65860. European Medicines Agency schedules Inaperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08162MIG.

UNSPSC 51152033 Inaperisone is a Commodity code applied to state and local purchases of pharmaceutical products and drug-related services, though recent solicitation activity shows a mismatch between the nominal code designation and actual procurement scope. The code appears in two recent state and local opportunities that focus on naloxone procurement and prescription-fulfillment program design rather than inaperisone specifically. State and local issuing bodies soliciting under this code include county health departments and state health and human services agencies. Seminole County, Florida, a representative county-level buyer, is procuring naloxone and drug deactivation systems through competitive bidding to support community health initiatives. The Texas Health and Human Services Commission, a state-level issuing body, is conducting market research on direct-to-manufacturer prescription fulfillment models. The scope of work encompasses pharmaceutical product supply (naloxone kits and deactivation systems for emergency response and public health), delivery and logistics coordination to designated county or state facilities, and vendor capability assessment for novel pharmacy benefit structures that bypass traditional pharmacy benefit managers and wholesalers.

Seminole County, Florida shows the most recent concrete procurement activity: an IFB (Invitation for Bid) posted June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries required to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued an RFI (Request for Information) posted April 3, 2026, to gather vendor input on direct-to-manufacturer prescription programs, which represents early-stage procurement intelligence gathering rather than a formal competitive solicitation. Geographic activity centers on Florida and Texas. The code's recent opportunity record is sparse and appears misaligned with the inaperisone designation; state and local procurement activity tagged to this code focuses on emergency-response pharmaceuticals, drug-disposal systems, and pharmacy program restructuring rather than inaperisone as a muscle relaxant product line.